• Login
    • Login
    Advanced Search
    View Item 
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Health Sciences (FHS)
    • View Item
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Health Sciences (FHS)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Trends in drug resistance codons in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Kenyan parasites from 2008 to 2012

    Thumbnail
    View/Open
    Abstract (272.5Kb)
    Fulltext (387.2Kb)
    Date
    2014
    Author
    Juma, DW
    Omondi, AA
    Ingasia, L
    Opot, B
    Cheruiyot, A
    Yeda, R
    Okudo, C
    Muiruri, P
    Ngalah, B
    Chebon, LJ
    Eyase, F
    Johnson, J
    Bulimo, WD
    Akala, HM
    Andagalu, B
    Kamau, E
    Type
    Article; en_US
    Language
    en
    Metadata
    Show full item record

    Abstract
    Background: Sulphadoxine-pyrimethamine (SP), an antifolate, was r eplaced by artemether-lumefantrine as the first-line malaria drug treatment in Kenya in 2004 due to the wide s pread of resistance. However, SP still remains the recommended drug for intermittent preventive treatment in pregnant women and infants (IPTP/I) owing to its safety profile. This study assessed the prevalence of mutations in dihydrofolate reductase(Pfdhfr )anddihydropteroate synthase(Pfdhps) genes associated with SP resistance in samples collected in Kenya between 2008 and 2012.Methods:Field isolates collected from Kisumu,Kisii, Kericho and Malindi district hospitals were assessed for genetic polymorphism at various loci within Pfdhfr and Pfdhpsgenes by sequencing. Results:Among the Pfdhfr mutations, codons N51I,C59R,S108N showed highest prevalence in all the field sites at 95.5%, 84.1% and 98.6% respectively. Pfdhfr S108N prevalence was highest in Kisii at 100 %. A temporal trend analysis showed steady prevalence of mutations over time except for codon Pfdhps 581 which showed an increase in mixed genotypes.Triple Pfdhfr N51I/C59R/S108N and double PfdhpsA437G/K540E had high prevalence rates of 86.6% and 87.9% respectively. The Pfdhfr/Pfdhps quintuple, N51I/C59R/S108N/A437G/K540 Emutantwhichhasbeenshowntobethemost clinically relevant marker for SP resistance was observed in 75.7% of the samples. Conclusion:SP resistance is still persistently highinwesternKenya,whichislikelyd ue to fixation of key mutations in the Pfdhfr and Pfdhps genes as well as drug pressure from other antifolate drugs being used for the treatment of malaria and other infections. In addition, there is emergence and increasing prevalence of new mutations in Kenyan parasite population. Since SP is used for IPTP/I, molecular surveillance and in vitro susceptibility assays must be sustained to provide information on the emergence and spread of SP resistance
    URI
    http://hdl.handle.net/11295/77293
    Citation
    Juma DW, Omondi AA, Ingasia L, Opot B, Cheruiyot A, Yeda R, Okudo C, Cheruiyot J, Muiruri P, Ngalah B, Chebon LJ, Eyase F, Johnson J, Bulimo WD, Akala HM, Andagalu B, Kamau E. "Trends in drug resistance codons in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Kenyan parasites from 2008 to 2012." Malar. J.. 2014;13:250.
    Publisher
    University of Nairobi
    Collections
    • Faculty of Health Sciences (FHS) [10417]

    Copyright © 2022 
    University of Nairobi Library
    Contact Us | Send Feedback

     

     

    Useful Links
    UON HomeLibrary HomeKLISC

    Browse

    All of UoN Digital RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Copyright © 2022 
    University of Nairobi Library
    Contact Us | Send Feedback